GE Healthcare has secured clearance from the European Medicines Agency for additional imaging modalities for its Rapiscan stress contrast agent.
Rapiscan is already cleared for SPECT myocardial perfusion imaging in adults. The expanded clearance now covers MRI, CT, and PET.
Rapiscan helps clinicians diagnose coronary artery disease, and it does not require weight and age-based modifications or an infusion pump, GE said.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
